BioSpace News Archive

Sionna Therapeutics today announced that it will present preclinical data on novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations at the Cystic Fibrosis Foundation’s North American Cystic Fibrosis Conference (NACFC) 2022 to be held November 3-5 at the Pennsylvania Convention Center in Philadelphia.

AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma study which demonstrates enhanced progression-free survival.

Microbion Corporation announced that the US Patent and Trademark Office issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane.

Exelixis, Inc. announced the expansion of its June 2021 Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb Company to include the use of the fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial, which is evaluating XL092 in combination with multiple immune checkpoint inhibitors in advanced solid tumors.

Abcuro, Inc. announced initiation of a Phase 1/2 dose escalation trial to evaluate the safety, tolerability, and proof-of-concept of ABC008 in patients with T cell large granular lymphocytic leukemia who suffer from anemia and/or neutropenia.

Fresenius Kabi announced it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem®.

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, announced the appointment of Allan Tsung, MD to its Scientific Advisory Board.

Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, announced the appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer.

Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced the close of a $21.5 million Series B financing.

Endpoint Health, Inc., a Precision-FirstTM therapeutics company, unveiled its newest precision immunology program targeting inflammation mediated by tissue factor -dependent intracellular signaling.